Methods and compositions for diagnosing prostate cancer
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.
1. A method for detecting prostate cancer, comprising:
a. detecting in a sample from a subject an expression level of an autoantibody to an antigen derived from FAM53B, 5′UTR-BMI, alpha-2-glycoprotein 1, or DCAMKL1; and,
b. detecting prostate cancer in said subject when said autoantibody to said antigen is overexpressed in said sample.
2. The method of claim 1 , further comprising detecting an expression level of an autoantibody to an antigen derived from eIF4G1, BRD2, or zinc finger protein 292.
3. The method of claim 1 , wherein said detecting of said autoantibody comprises detecting binding of an antibody to said autoantibody.
4. The method of claim 1 , wherein said sample is selected from the group consisting of a serum sample and a blood sample.
5. The method of claim 1 , wherein said antigen is on a microarray.
6. The method of claim 1 , further comprising providing a prognosis for said prostate cancer.
7. A method for detecting prostate cancer, comprising:
a. detecting in a sample from a subject a presence or absence of an autoantibody to an antigen derived from FAM53B, 5′UTR-BMI, alpha-2-glycoprotein 1, or DCAMKL1; and,
b. detecting prostate cancer in said subject when said autoantibody to said antigen is present in said sample.
8. The method of claim 7 , further comprising detecting a presence or absence of an autoantibody to an antigen derived from eIF4G1, BRD2, or zinc finger protein 292.
9. The method of claim 7 , wherein said detecting of said autoantibody comprises detecting binding of an antibody to said autoantibody.
10. The method of claim 7 , wherein said sample is selected from the group consisting of a serum sample and a blood sample.
11. The method of claim 7 , wherein said antigen is on a microarray.
12. The method of claim 7 , further comprising providing a prognosis for said prostate cancer.
13. The method of claim 1 , further comprising screening said subject for an increased PSA level.
14. The method of claim 1 , further comprising obtaining a biopsy from said subject.
15. The method of claim 1 , wherein said detecting of said autoantibody comprises binding said autoantibody to an antigen in an array of antigens.
16. The method of claim 15 , wherein said array of antigens is a phage-epitope array.
17. The method of claim 7 , wherein said detecting of said autoantibody comprises binding said autoantibody to an antigen in an array of antigens.
18. The method of claim 17 , wherein said array of antigens is a phage-epitope array.
19. A method for detecting prostate cancer in a subject comprising:
a. obtaining a serum or blood sample from said subject;
b. detecting in said serum or blood sample the presence or expression level of an autoantibody to an antigen derived from FAM53B, 5′UTR-BMI, alpha-2-glycoprotien 1, or DCAMKL1 by binding said autoantibody to an antigen in an array of antigens; and
c. detecting the presence of prostate cancer in said subject when said autoantibody to said antigen derived from FAM53B, 5′UTR-BMI, alpha-2-glycoprotien 1, or DCAMKL1 is present or overexpressed in said serum or blood sample.
20. The method of claim 19 , further comprising detecting a presence or expression level of an autoantibody to an antigen derived from eIF4G1, BRD2, or zinc finger protein 292 by binding said autoantibody to an antigen in an array of antigens.
21. The method of claim 19 , wherein said detecting of said autoantibody comprises detecting binding of an antibody to said autoantibody.
22. The method of claim 19 , wherein said array of antigens is a phage epitope array.